Coexistence of a novel SRBD1-ALK, ALK-CACNA1D double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report

Xiaohong Xie; Wenhui Guan; Wenting Huang; Juhong Jiang; Haiyi Deng; Yijia Li; Huixin Jiang; Ming Liu; Chengzhi Zhou

doi:10.1016/j.heliyon.2024.e24373

Coexistence of a novel SRBD1-ALK, ALK-CACNA1D double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report

Heliyon. 2024 Jan 14;10(2):e24373. doi: 10.1016/j.heliyon.2024.e24373. eCollection 2024 Jan 30.

Authors

Xiaohong Xie¹, Wenhui Guan^{1

2}, Wenting Huang², Juhong Jiang¹, Haiyi Deng¹, Yijia Li^{1

2}, Huixin Jiang^{1

2}, Ming Liu¹, Chengzhi Zhou¹

Affiliations

¹ State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Respiratory and Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, postcode, P.R.China.
² Guangzhou Medical University, Guangzhou, China.

Abstract

A Chinese male patient with advanced lung adenocarcinoma experienced disease progression one and a half years after receiving first-line immunochemotherapy. The second biopsy was performed and tissue immunohistochemistry revealed Anaplastic lymphoma kinase (ALK) expression in the cytoplasm of tumor cells, so he began to receive Alectinib treatment. Then the next generation sequencing found double fusion variants of S1 RNA binding domain 1 (SRBD1)- ALK and ALK- Calcium voltage-gated channel subunit alpha1 D (CACNA1D). After continuous Alectinib treatment for 7 months, almost complete response (CR) was achieved. The patient is currently taking Alectinib for 13 months, the condition is stable, and is waiting for the next cycle of efficacy evaluation.

Keywords: Alectinib; Anaplastic lymphoma kinase; Calcium voltage-gated channel subunit alpha1 D; Non-small cell lung cancer; S1 RNA binding domain 1.

Publication types

Case Reports